23 November 2017
News and Views
Links and Services
The most recent issue of Liver International investigates early prediction of sustained virological response with albinterferon-a-2b in patients with genotype 2/3 chronic hepatitis C.
Albinterferon-a-2b is a long-acting fusion polypeptide composed of albumin and interferon-a-2b. <
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors